Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by MannKind
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
September 30, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
September 18, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
September 10, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind to Present at Upcoming Conferences
August 27, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
August 14, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
August 07, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
July 31, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
July 30, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
June 22, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
June 05, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
May 29, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
May 08, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
May 06, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
May 01, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
April 30, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
April 29, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Repays Certain Debt Obligations
April 03, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Announces CFO Transition
March 26, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
March 11, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
March 05, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation Announces Participation at Upcoming Conferences
March 04, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
February 27, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
February 20, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
February 15, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
January 02, 2024
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
December 28, 2023
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation Reports 2023 Third Quarter Financial Results
November 07, 2023
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
November 06, 2023
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
October 31, 2023
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
October 30, 2023
From
MannKind
Via
GlobeNewswire
Tickers
MNKD
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright